The loss of two important factors of the PI3K/AKT pathway, phosphatase and tensin homolog (PTEN) and mammalian target of rapamycin (mTOR), drives the induction of PD-L1 protein levels in breast cancer cells, as well as tumor samples from breast cancer patients. This evidence concerns the gene PTEN and neoplasm.